SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

SCLCOctober 4, 2026

Longer OS in Asian than non-Asian patients given atezolizumab plus chemotherapy for extensive-stage SCLC

A pooled analysis of four phase 3 trials, published in Lung Cancer, found longer overall survival in Asian than in non-Asian patients given first-line atezolizumab plus carboplatin and etoposide for ES-SCLC, a difference that persisted after propensity score matching, while progression-free survival was similar in the two groups.
Share

In brief

  • Data from 707 patients with extensive-stage small-cell lung cancer (ES-SCLC), 363 Asian and 344 non-Asian, who received at least one dose of first-line atezolizumab with carboplatin and etoposide were pooled from four phase 3 trials, including IMpower133 and SKYSCRAPER-02.
  • Before matching, median overall survival (OS) was 15.3 months in Asian and 12.2 months in non-Asian patients (hazard ratio [HR] 0.80; p = 0.008).
  • After propensity score matching of 169 patients per group, median OS was 16.4 versus 11.3 months (HR 0.70; p = 0.004).
  • Median progression-free survival (PFS) after matching was similar, at 4.8 months in Asian and 5.1 months in non-Asian patients.
  • Grade 3–4 adverse events occurred in 82.8% of Asian and 60.9% of non-Asian patients, and grade 5 events in 0.6% and 4.7%.

Study at a glance

  • Design: Pooled analysis with propensity score matching by race (Asian, non-Asian)
  • Source trials: IMpower133, SKYSCRAPER-02, SKYSCRAPER-02C and a fourth phase 3 trial
  • Population: ES-SCLC, at least one dose of atezolizumab plus carboplatin and etoposide
  • Cohort: 363 Asian and 344 non-Asian patients; 169 per group after matching
  • Endpoints: OS, PFS and safety
  • Overall survival (matched): 16.4 versus 11.3 months; HR 0.70; p = 0.004
  • Progression-free survival (matched): 4.8 versus 5.1 months
  • Safety: Grade 3–4 adverse events 82.8% versus 60.9%; grade 5 events 0.6% versus 4.7%
  • Not reported: A hazard ratio for PFS, and the covariates used in the matching

Before matching, more never-smokers and fewer liver metastases in the Asian cohort

The 363 Asian patients also included more men and more patients with an Eastern Cooperative Oncology Group performance status of 1, and had a lower body mass index than the 344 non-Asian patients. All had received at least one dose of atezolizumab with carboplatin and etoposide in IMpower133, SKYSCRAPER-02, SKYSCRAPER-02C or the fourth pooled trial.

In this unmatched population, median OS was 15.3 months for Asian patients and 12.2 months for non-Asian patients (HR 0.80; p = 0.008). These baseline differences can affect survival, so the comparison was repeated after propensity score matching by race.

A median OS difference of 5.1 months after matching

With 169 patients in each group, median OS was 16.4 months in Asian patients and 11.3 months in non-Asian patients, for a hazard ratio of 0.70 (p = 0.004).

After matching, the hazard ratio was 0.70 against 0.80 before, and the difference in median OS was 5.1 months against 3.1 months, so matching did not remove the survival difference. The matched groups are subsets of the original cohorts, and the abstract does not report how well the matching balanced them.

Progression-free survival of about five months in both groups

Median PFS after matching was 4.8 months for Asian patients and 5.1 months for non-Asian patients, so the longer survival in the Asian group was not accompanied by longer PFS on first-line treatment.

The abstract does not describe what treatment patients received after progression. It therefore cannot show whether later lines of therapy, or differences in how they were used across regions, contributed to the OS difference seen after a similar time to progression.

More grade 3–4 adverse events in Asian patients, more grade 5 events in non-Asian patients

Almost every patient had at least one adverse event, 98.8% of Asian and 100% of non-Asian patients. Grade 3–4 events occurred in 82.8% of the Asian group against 60.9% of the non-Asian group.

The pattern reversed for fatal events: grade 5 adverse events were reported in 0.6% of Asian and 4.7% of non-Asian patients. The abstract does not give the causes of these deaths.

“This analysis demonstrates the utility of atezolizumab plus chemotherapy for ES-SCLC and longer OS for Asian patients.”Zhang et al., Lung Cancer (2026)

An observational comparison drawn from randomised trials

Every patient in the analysis was treated within a phase 3 trial, but race was not a randomised factor in any of them. The comparison between Asian and non-Asian patients is therefore observational, and propensity score matching can balance only the characteristics that were measured.

The authors’ rationale is that differences in tumour biology, the tumour microenvironment and immunology can make race affect outcomes. The abstract reports no direct measure of these, so the analysis describes an association between race and survival on atezolizumab plus chemotherapy, and it does not identify the mechanism behind it.

Sources

  1. Lung Cancer. Atezolizumab plus chemotherapy for Asian vs. non-Asian patients with extensive-stage small-cell lung cancer: A propensity score matched pooled analysis of four phase 3 trials (2026-09-01). doi.org

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty Stephen Liu, Martin Reck and Charles Rudin.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Jacob Sands, Solange Peters and Martin Reck
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2026 Year in Review

Learn more about the event

S. PetersJ. SandsM. Reck
Nov 13 2026
ILCS 2026
Advanced NSCLCResectable NSCLCSCLC

Panel: open questions & patient cases

Nov 13 2026
ILCS 2026
SCLC

Debate: which is the better choice in 1L ES-SCLC?

G. MountziosA. Dingemans
Nov 13 2026
ILCS 2026
SCLC

The emerging role of T-cell engagers and ADCs in SCLC

N. Frost
Nov 13 2026
ILCS 2026
Resectable NSCLCImmunotherapies

Latest options in early-stage NSCLC: novel IO approaches for improved outcomes

S. Patel
Prof. Martin Reck
Nov 04 2026
SPONSORED EXPERT TALK
Resectable NSCLCImmunotherapies

MDT-BRIDGE in Resectable and Borderline Resectable NSCLC

Prof. Martin Reck presents and discusses the phase 2 MDT-BRIDGE trial in resectable and borderline resectable non-small cell lung cancer in this on-demand expert talk.

M. Reck
Dr. Jacob Sands
Nov 04 2026
SPONSORED INTERVIEW
SCLCImmunotherapies

New Therapy Options in SCLC and AE Management

Dr. Jacob Sands discusses new treatment options in small cell lung cancer and the management of their adverse events in this on-demand expert interview.

J. Sands
Oct252026
ESMO 2026 SYMPOSIUM
SCLCImmunotherapies

SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era

A symposium at ESMO Congress 2026 on small-cell lung cancer, from immunotherapy standards to the emerging era of DLL3 T-cell engagers. Recording to follow.

M. ReckS. PetersG. MountziosN. Reguart
Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
ILCS 2025
SCLC

Reshaping Approaches in SCLC with the Latest Advances in LS- and ES-Disease

} 34 min

R. Manochakian
Sep 26 2025
ILCS 2025
Immunotherapies

The Role of IO Added to Chemoradiation in Unresectable Stage III NSCLC

} 28 min

A. Filippi
Sep 26 2025
ILCS 2025
Immunotherapies

Tailoring IO in Res. NSCLC: Personalized Approaches for Improved Outcomes

} 36 min

P. Forde
IO in NSCLC by Solange Peters, Jordi Remon, Patrick Forde
Jun 25 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCImmunotherapies

Immunotherapies in NSCLC

} 1h 47 min

P. FordeJ. RemonS. Peters
SCLC by Solange Peters, Giannis Mountzios, Jacob Sands
Jun 17 2025
VIRTUAL ROUNDTABLE
SCLCImmunotherapies

Small Cell Lung Cancer

} 1h 35 min

G. MountziosJ. SandsS. Peters
Stephen Liu
Oct 04 2024
ILCS 2024
SCLC

Reshaping Our Approaches in SCLC: Latest Therapeutic Options and Future Strategies

} 25 min

S. Liu
Jordi Remon
Oct 04 2024
ILCS 2024
Immunotherapies

Tailoring IO in Resectable NSCLC: Personalized Approaches for Improved Outcomes

} 25 min

J. Remon
Nov 13 2026
ILCS 2026
Advanced NSCLC

New compounds and combinations for non-oncogene-addicted advanced NSCLC

A. Cortellini
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCResectable NSCLCTargeted Therapies

One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey

M. Hochmair
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C

A. Curioni-Fontecedro
Articles
Nov 16 2026
RESEARCH
Immunotherapies

Lenvatinib plus pembrolizumab gave a median PFS of 22.1 months in pretreated thymic carcinoma and B3 thymoma

J. RemonN. GirardN. Reguart
Charles Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide

C. Rudin
Nov 04 2026
RESEARCH
Advanced NSCLCImmunotherapies

Local ablative therapy alone after durvalumab was followed by an mOS of 18.7 months in oligoprogressive NSCLC

A. FilippiL. Hendriks
Nikolaj Frost
Oct 31 2026
RESEARCH
Resectable NSCLCImmunotherapies

KEYNOTE-867 tested pembrolizumab with SBRT in unresected stage I or II NSCLC

N. Frost
Charles Rudin
Oct 30 2026
RESEARCH
SCLCImmunotherapies

Tarlatamab gave an mOS of 13.6 months against 8.4 with chemotherapy in SCLC at extended DeLLphi-304 follow-up

C. RudinG. Mountzios
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

M. ReckN. GirardA. Filippi
Oct 29 2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies

Early ctDNA clearance was associated with longer event-free survival in resectable NSCLC in NeoCOAST-2

T. CasconeP. Forde
Oct 29 2026
RESEARCH
Advanced NSCLCImmunotherapies

Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE

M. Pérol
Oct 27 2026
RESEARCH
SCLCImmunotherapies

Tarlatamab added to durvalumab maintenance extended OS in extensive-stage SCLC

J. SandsM. PérolA. Dingemans
Oct 23 2026
RESEARCH
SCLCImmunotherapies

KEYVIBE-008 tested vibostolimab coformulated with pembrolizumab plus chemotherapy in first-line ES-SCLC

J. SandsM. Reck
Oct 21 2026
SPONSORED
Advanced NSCLCImmunotherapies

The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC

A. Curioni-Fontecedro
Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 19 2026
RESEARCH
Advanced NSCLCImmunotherapies

Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update

H. Horinouchi
Oct 07 2026
RESEARCH
BiomarkersSCLC

IASLC pathologists propose a grade 3 category for lung carcinoids with more than 10 mitoses

P. Hofman
Oct 06 2026
RESEARCH
Advanced NSCLCImmunotherapies

Two-thirds of patients with PD-L1-high NSCLC received first-line immunotherapy alone in a real-world survey

D. Rodríguez-Abreu
Oct 05 2026
RESEARCH
SCLCImmunotherapies

Second-line therapy in ES-SCLC gave a median OS of 7.1 months in the Austrian LALUCA registry

M. Hochmair
Nikolaj Frost
Oct 04 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

Checkpoint inhibitors were associated with longer survival in NSCLC after allogeneic stem cell transplantation

N. FrostM. ReckA. Cortellini
Oct 02 2026
RESEARCH
Advanced NSCLCBiomarkersImmunotherapies

High tumour mutational burden was associated with more frequent and earlier immune-related adverse events in advanced NSCLC

B. Ricciuti
Sep 30 2026
RESEARCH
Advanced NSCLCSCLCADCs

Pulmonary adverse events affected almost a third of lung cancer patients treated with ADCs in a 24-study meta-analysis

C. Rolfo
Martin Reck
Sep 28 2026
RESEARCH
Resectable NSCLCImmunotherapies

AEGEAN’s second interim analysis kept the EFS benefit of perioperative durvalumab, on an OS reading that crosses 1

M. ReckM. Hochmair